Evaluation of the performance of drug-drug interaction screening software in community and hospital pharmacies

Journal of Managed Care Pharmacy

Volumn 12, Issue 5, 2006, Pages 383-389

  Abarca, Jacob ^a   Colón, Lisa R ^b   Wang, Victoria S ^c   Malone, Daniel C ^a   Murphy, John E ^a   Armstrong, Edward P ^a  

^a UNIVERSITY OF ARIZONA   (United States)

^b Walgreen Company   (United States)

^c Costco Pharmacy ^*  (United States)

Author keywords

Community pharmacy; Drug interactions; Drug utilization review alerts; Hospital pharmacy; Patient safety

Indexed keywords

ATENOLOL; AZITHROMYCIN; CARBAMAZEPINE; CISAPRIDE; CLOMIPRAMINE; DIGOXIN; ERGOTAMINE; ERYTHROMYCIN; FLUCONAZOLE; FLUVOXAMINE; GUAIFENESIN; KETOCONAZOLE; OMEPRAZOLE; PETHIDINE; PHENELZINE; PIMOZIDE; RIFAMPICIN; SILDENAFIL; SIMVASTATIN; TACROLIMUS; THEOPHYLLINE; VERAPAMIL;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; ASTHMA; CLINICAL ARTICLE; COMMUNITY CARE; COMPUTER PROGRAM; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DEPRESSION; DRUG ANTAGONISM; DRUG FORMULATION; DRUG RESEARCH; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EPILEPSY; FEMALE; GASTROESOPHAGEAL REFLUX; HEALTH CARE SYSTEM; HEART ATRIUM FIBRILLATION; HOSPITAL PHARMACY; HUMAN; HYPERTENSION; MALE; MEDICAL ASSESSMENT; MEDICAL RECORD; NEISSERIACEAE INFECTION; OBSESSIVE COMPULSIVE DISORDER; PATIENT SAFETY; RISK ASSESSMENT; SCHOOL CHILD; SCREENING TEST; SENSITIVITY AND SPECIFICITY; COMPARATIVE STUDY; DRUG INTERACTION; EVALUATION; HOSPITAL INFORMATION SYSTEM; MEDICAL INFORMATION SYSTEM; PHARMACY; STATISTICS;

CLINICAL PHARMACY INFORMATION SYSTEMS; COMMUNITY PHARMACY SERVICES; DRUG INTERACTIONS; HOSPITAL INFORMATION SYSTEMS; HUMANS; PHARMACIES; PHARMACY SERVICE, HOSPITAL; SOFTWARE;

EID: 33845499756     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2006.12.5.383     Document Type: Article

References (20)

1. Institute of Medicine. To Err Is Human: Building a Safer Health System. Washington, D.C.: Institute of Medicine; 1999.
2. Weideman RA, Bernstein IH, McKinney WP. Pharmacist recognition of potential drug interactions. Am J Health Syst Pharm. 1999;56(15):1524-29.
3. Glassman PA, Simon B, Belperio P, Lanto A. Improving recognition of drug interactions: benefits and barriers to using automated drug alerts. Med Care. 2002;40:1161-71.
4. Chrischilles EA, Fulda TR, Byrns PJ, Winckler SC, Rupp MT, Chui MA. The role of pharmacy computer systems in preventing medication errors. J Am Pharm Assoc. 2002;42(3):439-48.
5. Jankel CA, Martin BC. Evaluation of six computerized drug interaction screening programs. Amer J Hosp Pharm. 1992;49(6):1430-35.
6. Lyles A, Zuckerman IH, DeSipio SM, Fulda T. When warnings are not enough: primary prevention through drug use review. Health Aff. 1998;17(5):175-83.
7. Abarca J, Malone DC, Armstrong EP, et al. Concordance of severity ratings provided in four drug interaction compendia. J Am Pharm Assoc. 2004;44(2):136-41.
8. Fulda TR, Baluck RJ, Vander Zanden J, Parker S, Byrns PJ. Disagreement among drug compendia on inclusion and ratings of drug-drug interactions. Curr Ther Res. 2000;61(8):540-48.
9. Hazlet TK, Lee TA, Hansten PD, Horn JR. Performance of community pharmacy drug interaction software. J Am Pharm Assoc. 2001;41:200-04.
10. Mangini RJ. Drug Interaction Facts. St. Louis, MO: Facts and Comparisons; 2001.
11. Hansten PD, Horn JR. Drug Interactions: Analysis and Management. St. Louis, MO: Facts and Comparisons; 2001.
12. Evaluations of Drug Interactions. St. Louis, MO: First DataBank; 2001.
13. Moore LL, Minne K, Moore KB. DRUG-REAX System. Greenwood Village, CO: Micromedex; 2001.
14. Pagano M, Gauvreau K. Principles of Biostatistics. Belmont, CA: Duxbury Press; 1993.
15. Barrons R. Evaluation of personal digital assistant software for drug interactions. Am J Health Syst Pharm. 2004;61(4):380-85.
16. Yu DT, Peterson JF, Seger DL, Gerth WC, Bates DW. Frequency of potential azole drug-drug interactions and consequences of potential fluconazole drug interactions. Pharmacoepidemiol Drug Saf. 2005;14(11):755-67.
17. Armstrong EP, Denemark CR. How pharmacists respond to on-line, realtime DUR alerts. J Am Pharm Assoc. 1998;38:149-54.
18. Peng CC, Glassman PA, Marks IR, Fowler C, Castiglione B, Good CB. Retrospective drug utilization review: incidence of clinically relevant potential drug-drug interactions in a large ambulatory population. J Manag Care Pharm. 2003;9(6):513-22.
19. Malone DC, Hutchins DS, Haupert H, et al. Assessment of potential drugdrug interactions with a prescription claims database. Am J Health Syst Pharm. 2005;62(19):1983-91.
20. Egger T, Dormann H, Ahne G, et al. Identification of adverse drug reactions in geriatric inpatients using a computerised drug database. Drugs & Aging. 2003;20(10):769-76.